ACADIA Pharmaceuticals (ACAD) Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings, valuation and community ranking.

Is ACAD or ASND more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Ascendis Pharma A/S's net margin of -104.54%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Ascendis Pharma A/S's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%
Ascendis Pharma A/S	-104.54%	N/A	-39.23%

Does the media refer more to ACAD or ASND?

In the previous week, ACADIA Pharmaceuticals had 6 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 13 mentions for Ascendis Pharma A/S. ACADIA Pharmaceuticals' average media sentiment score of 1.10 beat Ascendis Pharma A/S's score of 1.00 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ACADIA Pharmaceuticals	9 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ascendis Pharma A/S	6 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility & risk, ACAD or ASND?

ACADIA Pharmaceuticals has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500.

Does the MarketBeat Community favor ACAD or ASND?

ACADIA Pharmaceuticals received 450 more outperform votes than Ascendis Pharma A/S when rated by MarketBeat users. Likewise, 73.07% of users gave ACADIA Pharmaceuticals an outperform vote while only 66.87% of users gave Ascendis Pharma A/S an outperform vote.

Company	Underperform	Outperform
ACADIA Pharmaceuticals	Outperform Votes 898 73.07%	Underperform Votes 331 26.93%
Ascendis Pharma A/S	Outperform Votes 448 66.87%	Underperform Votes 222 33.13%

Do analysts rate ACAD or ASND?

ACADIA Pharmaceuticals currently has a consensus target price of $23.93, indicating a potential upside of 62.48%. Ascendis Pharma A/S has a consensus target price of $204.67, indicating a potential upside of 24.00%. Given ACADIA Pharmaceuticals' higher probable upside, analysts plainly believe ACADIA Pharmaceuticals is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ACADIA Pharmaceuticals	0 Sell rating(s)	8 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.50
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.93

Do institutionals & insiders have more ownership in ACAD or ASND?

96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Which has preferable earnings & valuation, ACAD or ASND?

ACADIA Pharmaceuticals has higher revenue and earnings than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ACADIA Pharmaceuticals	$957.80M	2.57	-$61.29M	$1.36	10.83
Ascendis Pharma A/S	$363.64M	27.67	-$409.12M	-$7.10	-23.25

Summary

ACADIA Pharmaceuticals beats Ascendis Pharma A/S on 13 of the 17 factors compared between the two stocks.